Skip to content

Development and validation of noninvasive diagnostic methods for endometriosis

Development and validation of noninvasive diagnostic methods for endometriosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093810
Enrollment
Unknown
Registered
2024-12-12
Start date
2024-06-18
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis

Interventions

control group:
Patients with endometriosis:

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Age > 18 - < 50 years old, sexually active; 2.Patients signed the study's informed consent form and completed a symptom and quality of life questionnaire; 3.Infertility, abdominal pain, and abnormal bleeding symptoms (medical investigation); 4.Sampling is performed during non-menstrual periods. 5.Endometriosis or other gynecological conditions requiring surgery are suspected and surgery has been scheduled; 6.Consent to surgery to confirm endometriosis status/stage or absence of endometriosis (control group) for grouping; 7.Ideally, initial patients who have not undergone extensive hormone therapy;

Exclusion criteria

Exclusion criteria: 1.Age 50; 2.Pregnant women excluded as controls or patients; 3.Patients infected with acquired immunodeficiency virus ( HIV) or other viral pathogens /STDs , acute inflammatory conditions, including genital tract infections and oral infections, etc, autoimmune disease, and active cancer; 4.Failure to comply with study protocols and follow-up requirements; 5.Patients who object to medical history collection and data requests; 6.Patients undergoing chemotherapy and/or radiotherapy (withdrawal period is 4 weeks). 7.Patients who do not show any symptoms and/or are unable to undergo surgery;

Design outcomes

Primary

MeasureTime frame
miRNA expression;

Secondary

MeasureTime frame
New miRNA;

Countries

China

Contacts

Public ContactJinghua Shi

Peking Union Medical College Hospital

elisa_1984@163.com+86 10 69155749

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026